Rapport Therapeutics stock gains 3.74%; trial win reported Tuesday morning

Rapport Therapeutics stock retains a bearish daily bias after the close on Monday, October 19, 2026, at $28.6 , with price sitting below all major exponential averages. Trial reports published after the close add a separate development. Monday’s completed chart does not capture the response to those reports. It opened at $27.57, traded between a low of $27.57 and a high of $29.10, and closed at $28.60, against a previous close of $27.57.

Source: The Cryptonomist